Compugen Ltd

Compugen maintains a strong liquidity position, with $90.6 million in cash and equivalents, representing 57.9% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 6.56 suggests a robust ability to meet short-term obligations. Profitability metrics are strong, with a return on equity (ROE) of 34.4% and a return on assets (ROA) of 22.6%. These figures exceed the typical thresholds for biotechnology firms, which often prioritize R&D over immediate profitability. Gross profit margin is 87.3%, and operating margin is 43.0%, both of which are in line with industry norms for early-stage biotech companies. Geographically, Compugen's revenue is not disclosed by region in the latest financials, but the company is headquartered in Israel and operates globally. The firm's revenue is primarily derived from licensing and collaboration agreements, with no single customer accounting for more than 10% of total revenue. Growth in the current fiscal year is expected to be modest, with no significant revenue increase projected. The company's focus remains on advancing its pipeline through partnerships rather than direct commercialization. Looking ahead, the next fiscal year is expected to show similar trends, with the company likely to remain in the R&D phase for most of its programs. Risk factors are limited, with no immediate liquidity or dilution concerns. The company has no long-term debt and a low dilution risk, as shares outstanding for both basic and diluted are identical. No recent equity issuance or ATM programs have been disclosed, and there are no dilution-related flags in the latest filings. Recent events include the continued development of its immuno-oncology pipeline, with several programs in preclinical and clinical stages. The company has also entered into new licensing agreements, which are expected to provide future revenue streams. No material adverse events were disclosed in the latest 10-K filing.